Epitopea Appoints Cancer Expert Lisa Butterfield to Advisory Board

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors, today announced the appointment of Lisa Butterfield to its Scientific Advisory Board (SAB). A highly respected leader in immuno-oncology, Dr. Butterfield brings extensive expertise in cancer vaccines, immune profiling, biomarker development and cellular therapies for solid tumor types. Her appointment comes as Epitopea advances its pipeline of RNA-based cancer immunotherapies, including its lead candidate CryptiVax™-1001, for high-grade serous ovarian cancer.

Epitopea, a pioneering biotechnology company focused on revolutionizing cancer treatment, has recently announced the enhancement of its Scientific Advisory Board. The spotlight of this announcement is the appointment of Dr. Lisa Butterfield, a distinguished expert in the field of cancer immunotherapy, who brings a wealth of knowledge and experience to the board. This strategic move reflects Epitopea's commitment to advancing its research and development efforts in the realm of oncology.

Dr. Butterfield, with her remarkable track record, has been at the forefront of cancer research for several years. She is known for her significant contributions to the understanding of tumor immunology and the development of cancer vaccines, which have paved the way for innovative treatment options. Her appointment is expected to bolster Epitopea's capabilities in translating scientific discoveries into effective therapeutic interventions.

The addition of Dr. Butterfield to the Scientific Advisory Board comes at a crucial time as Epitopea seeks to expand its pipeline of therapies targeting cancer. Her insights and expertise in T-cell therapy and the tumor microenvironment are particularly valuable as the company endeavors to develop novel therapeutic strategies that enhance the body’s natural ability to fight cancer.

Moreover, Dr. Butterfield has held various leadership roles in prestigious organizations and has a robust academic background, including serving as the Chief Scientific Officer at a prominent cancer research institute. Her extensive network and collaborative spirit are regarded as assets that can facilitate partnerships and foster innovation within Epitopea.

The company’s CEO expressed enthusiasm about Dr. Butterfield's appointment, highlighting that her experience aligns perfectly with Epitopea’s mission to develop transformative therapies for patients suffering from cancer. The CEO noted that having someone of her caliber on the board is a testament to the company’s growth and its dedication to pioneering advancements in cancer treatment.

Epitopea is currently focused on harnessing the power of T-cell therapy and is investigating new approaches to enhance the efficacy of existing treatments. The integration of Dr. Butterfield into the board is therefore seen as a catalytic force that will drive the company's research initiatives and propel it closer to achieving its goal of delivering groundbreaking therapies to patients.

In conclusion, Dr. Lisa Butterfield's appointment to Epitopea's Scientific Advisory Board marks a pivotal advancement for the company. Her wealth of experience and esteemed reputation in the cancer research community will undoubtedly steer Epitopea towards new heights in its mission to develop innovative cancer therapies. As the biotech landscape continues to evolve, the insights from leading authorities like Dr. Butterfield will be essential in navigating the challenges of cancer treatment and improving patient outcomes.